AGA NSAID advisory
This article was originally published in The Tan Sheet
Healthcare providers need to carefully consider the associated risks of NSAIDs before prescribing them, a multi-disciplinary panel of experts convened by the American Gastroenterological Association Institute says. The findings of the panel "Consensus Development Conference on the Use of Nonsteroidal Anti-Inflammatory Agents, Including Cyclooxygenase-2 Enzyme Inhibitors and Aspirin," were published in the September Clinical Gastroenterology and Hepatology. The panel provided recommendations for healthcare providers, which include instituting gastroprotection methods, such as proton pump inhibitors for patients at high-risk of GI complications. The AGA panel was supported through an unrestricted educational grant from TAP Pharmaceutical Products...
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.